Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 41071735.
- Also identified by DOI 10.1093/cid/ciaf376 and PMC identifier 12640205.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The National Institute of Allergy and Infectious Diseases has funded a clinical trial infrastructure to advance products and strategies to improve treatment and prevention of infectious diseases. This infrastructure includes dedicated research clinics, such as the Vaccine and Treatment Evaluation Units (VTEUs). For more than 6 decades, the VTEUs have maintained quality systems to advance investigational products to licensure by conducting trials that de-risk private sector investment in clinical development. They have developed novel clinical trial approaches, such as controlled human challenge models, responded rapidly to pandemic threats, engaged impacted communities across a variety of diseases, and provided mentorship and training to the next generation of clinical investigators.
Medical subject headings
- Clinical Trials as Topic
- Vaccines
- Vaccine Development